{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T15:08:08Z","timestamp":1795014488728,"version":"4.9.1"},"reference-count":21,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,10,12]]},"DOI":"10.1182\/blood-2017-02-765032","type":"journal-article","created":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T20:40:27Z","timestamp":1503348027000},"page":"1768-1771","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":57,"title":["Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results"],"prefix":"10.1182","volume":"130","author":[{"given":"Srdan","family":"Verstovsek","sequence":"first","affiliation":[{"name":"Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Insubria, Varese, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXII, Bergamo, Italy;"},{"name":"Dipartimento di Oncologia ed Emato-Oncologia, University of Milan, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Barosi","sequence":"additional","affiliation":[{"name":"Center for the Study of Myelofibrosis, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo Foundation, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Rumi","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy;"},{"name":"Department of Hematology Oncology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Gattoni","sequence":"additional","affiliation":[{"name":"Department of Oncology, Ospedale Santo Spirito, Casale Monferrato, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Pieri","sequence":"additional","affiliation":[{"name":"Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, Florence, Italy;"},{"name":"Department of Experimental and Clinical Medicine, Laboratorio Congiunto for Myeloproliferative Neoplasm, University of Florence, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Zhen","sequence":"additional","affiliation":[{"name":"Incyte Corporation, Wilmington, DE; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Granier","sequence":"additional","affiliation":[{"name":"Incyte Corporation, Wilmington, DE; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Assad","sequence":"additional","affiliation":[{"name":"Incyte Corporation, Wilmington, DE; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy;"},{"name":"Department of Hematology Oncology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[{"name":"Clinical Research Foundation (FROM), Ospedale Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, Florence, Italy;"},{"name":"Department of Experimental and Clinical Medicine, Laboratorio Congiunto for Myeloproliferative Neoplasm, University of Florence, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"20","key":"2019111905505408400_B1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019111905505408400_B2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"issue":"17","key":"2019111905505408400_B3","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111905505408400_B4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111905505408400_B5","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/leu.2013.99","article-title":"Personalized management of essential thrombocythemia-application of recent evidence to clinical practice","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"2019111905505408400_B6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2141.2010.08430.x","article-title":"Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance\/intolerance to hydroxycarbamide in essential thrombocythaemia","volume":"152","author":"Hern\u00e1ndez-Boluda","year":"2011","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111905505408400_B7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"17","key":"2019111905505408400_B8","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"9464","key":"2019111905505408400_B9","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"9","key":"2019111905505408400_B10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111905505408400_B11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111905505408400_B12","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111905505408400_B13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"2019111905505408400_B14","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/cncr.28441","article-title":"A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea","volume":"120","author":"Verstovsek","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"2019111905505408400_B15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1177\/2040620715580068","article-title":"Advances and challenges in the management of essential thrombocythemia","volume":"6","author":"Birgeg\u00e5rd","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"2019111905505408400_B16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","article-title":"Myeloproliferative neoplasms (MPNs) have a significant impact on patients\u2019 overall health and productivity: the MPN Landmark survey","volume":"16","author":"Mesa","year":"2016","journal-title":"BMC Cancer"},{"issue":"23","key":"2019111905505408400_B17","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019111905505408400_B18","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3892\/ol.2014.2801","article-title":"Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms","volume":"9","author":"Zhang","year":"2015","journal-title":"Oncol Lett"},{"issue":"1","key":"2019111905505408400_B19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12185-008-0222-0","article-title":"Comparison of clinicopathologic findings according to JAK2 V617F mutation in patients with essential thrombocythemia","volume":"89","author":"Cho","year":"2009","journal-title":"Int J Hematol"},{"issue":"22","key":"2019111905505408400_B20","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"key":"2019111905505408400_B21","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/asheducation-2011.1.208","article-title":"Genetic and epigenetic complexity in myeloproliferative neoplasms","volume":"2011","author":"Cross","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/15\/1768\/1402719\/blood765032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/15\/1768\/1402719\/blood765032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T05:51:04Z","timestamp":1574142664000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/15\/1768\/36383\/Ruxolitinib-for-essential-thrombocythemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,12]]},"references-count":21,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2017,10,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-02-765032","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732243666.793541429","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,12]]}}}